<DOC>
	<DOC>NCT00776347</DOC>
	<brief_summary>The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.</brief_summary>
	<brief_title>Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>DLB patients: who fulfill the diagnostic criteria of DLB 60 to 85 years old righthanded Clinical Dementia Rating (CDR) â‰§ 0.5 Mini Mental State Examination (MMSE) score from 10 to 26 Normal Controls: who are independent who have no subjective or objective cognitive impairment 60 to 85 years old righthanded MMSE score over 24 DLB patients: who have diabetes mellitus who have pathological change on MRI other than brain atrophy who have complication or history of dementia other than DLB, psychiatric disease, and physical disorder that affect brain function who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety who have severe digestive ulcus who have severe bronchitic asthma or obstructive lung disease who have no caregiver who knows patient's condition well Normal Controls: who have diabetes mellitus who have taken donepezil before who have abnormal findings on MRI who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Dementia with Lewy bodies (DLB)</keyword>
	<keyword>FDG-PET</keyword>
</DOC>